Temafloxacin

CHEMBL277100 Phase 4 अनुमोदित Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
417.4 g/mol
LogP
0.6
Phase
4

Temafloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, producing bactericidal effects against a broad spectrum of gram-positive and gram-negative organisms. It was withdrawn from the market in 1992 due to a rare but serious syndrome of hemolytic anemia, hypoglycemia, and coagulopathy (temafloxacin syndrome). Its pharmacological mechanism is similar to other fluoroquinolones but its idiosyncratic toxicity profile led to permanent market withdrawal.

आणविक भार

417.4000 g/mol

LogP

0.60

TPSA

72.90 Ų

लिपिंस्की RO5

उत्तीर्ण

क्रिया का तंत्र

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1

InChI

InChI=1S/C21H18F3N3O3/c1-11-9-26(5-4-25-11)19-8-18-13(7-16(19)24)20(28)14(21(29)30)10-27(18)17-3-2-12(22)6-15(17)23/h2-3,6-8,10-11,25H,4-5,9H2,1H3,(H,29,30)

Molecular Formula

C21H18F3N3O3

HBD / HBA

2 / 9

घूर्णनीय बंधन

3

भारी परमाणु

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

Temafloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, producing bactericidal effects against a broad spectrum of gram-positive and gram-negative organisms. It was withdrawn from the market in 1992 due to a rare but serious syndrome of hemolytic anemia, hypoglycemia, and coagulopathy (temafloxacin syndrome). Its pharmacological mechanism is similar to other fluoroquinolones but its idiosyncratic toxicity profile led to permanent market withdrawal.

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

Yes, Temafloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL277100. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 60021. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.